In summary, our analysis demonstrates that an unselected BRCA1/BRCA2/PALB2 multigene testing strategy is highly cost-effective in China, can prevent thousands of BC/OC cases/deaths, and provides a basis for policy change to implement this. Here, BRCA1 is linked to breast cancer.